Jun 03, 2019 / 11:30PM GMT
Arvind Sood - Amgen Inc. - VP of IR
Okay. Good evening, everybody. Let me be the first to welcome you to our event this evening. Over the last couple of days, we have had a chance to present some important data, with the most recent being, of course, the AMG 510 data that we presented this morning. Let me just quickly review our list of speakers. And I would just like to mention that unfortunately, Dave Reese, who's our Head of R&D, is not able to make it to this event. Because of a family emergency, he had to go back to the West coast.
But we have Dr. Greg Friberg, who is our Vice President of clinical -- oncology clinical development, is here with us. And Greg is going to make some introductory comments followed by Dr. Marwan Fakih, who you may have seen this morning, he actually presented the 510 data.
Dr. Fakih is actually a Professor in the Department of Medical Oncology at the City of Hope in Duarte, California. And after Dr. Fakih's presentation, Greg will come back and talk about 2 of our BiTE programs. He'll talk about AMG 212 as well as AMG 420. And then after that, we
Amgen Inc Investor Event at ASCO 2019 Transcript
Jun 04, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers